A combined treatment of IL-2/JES6 immunocomplexes and chemotherapy hampers the tumor growth and induces KILR CD8+ T cells.(A–C) On day 0, BALB/C mice were inoculated with BCL1 leukemia cells. On days 11 and 24 post inoculation, mice received doxorubicin (Dox), with or without anti-CD4 or anti-CD8...
more
A combined treatment of IL-2/JES6 immunocomplexes and chemotherapy hampers the tumor growth and induces KILR CD8+ T cells.(A–C) On day 0, BALB/C mice were inoculated with BCL1 leukemia cells. On days 11 and 24 post inoculation, mice received doxorubicin (Dox), with or without anti-CD4 or anti-CD8 depletion mAbs. On three consecutive days, mice were treated with IL-2/JES6. (A) Scheme of the experiment. (B) Survival curves. n = 16 mice per group in two independent experiments with the exception of “Dox + IL-2/JES6 + αCD8” conditions where three mice in the second experiment did not tolerate anti-CD8 administration for unknown reasons and were removed. (C) On day 30, spleens of mice from control (n = 7), Dox-treated (n = 8), and Dox + IL-2/JES6-treated (n = 6) groups were collected and analyzed by flow cytometry. Left: expression of KLRK1, CD49d, and IL-7R on CD44+ CD8+ T cells. Representative staining. Right: percentage of KLRK1+ CD49d-, KLRK1+ CD49d+, and KLRK1+ IL-7R+ cells out of CD44+ CD8+ T cells. Two independent experiments. (D–H) On day 0, C57Bl/6J mice were inoculated with B16F10 melanoma cells. On day 6, mice received doxrubicin (Dox). On three consecutive days, mice were treated with IL-2/JES6. (D) Scheme of the experiment showing also the eventual treatment with anti-CD4 or anti-CD8 depletion mAb relevant for Figure 7—figure supplement 1B. (E) Survival curves. n = 16 mice per group in two independent experiments. (F–H) On day 11, spleens and tumors of mice from control, Dox-treated, and Dox + IL-2/JES6-treated groups (n = 8 per group) were collected and analyzed by flow cytometry. Two independent experiments. (F) Top: expression of KLRK1 and granzyme B on splenic CD8+ T cells. Representative dot plot. Bottom: percentage of KLRK1+ GZMB B+ cells out of total CD8+ T cells. (G) Top: expression of KLRK1 and CD49d on intratumoral CD8+ T cells. Representative dot plot. Bottom: percentage of KLRK1+ CD49d- cells out of total CD8+ T cells. (H) IL-7R and GZMB expression on intratumoral KLRK1+ CD8+ T cells. Representative histograms and geometric mean fluorescence intensity (MFI) are shown. Statistical significance was calculated by log-rank (Mantel–Cox) test (survival B, E), or Kruskal–Wallis test (C, F–H) (p-value is shown in italics) with Dunn’s post-test (*<0.05, **<0.01, ***<0.001). Median is shown.The effects of combined treatment of tumor-bearing mice with IL-2/JES6 immunocomplexes and doxorubicine.(A) In experiments described in Figure 7A and B, BCL1 IgM/IgD in the serum on days 28, 54, and 94–96 post tumor inoculation was detected by ELISA. n = 16 mice per group in two independent experiments with two exceptions: (i) 'Dox + IL-2/JES6 + αCD4' conditions on day 54 where the analysis failed for the second experiment and thus, n = 8 mice and (ii) control conditions on day 54, when one mouse was not analyzed for technical reasons and thus, n = 15. The statistical significance was calculated using chi-square test (two groups of the outcomes: mice with undetectable BCL1 vs. mice with detectable BCL1 or dead), p-value is shown in italics. (B) Addition data for the experiment shown in Figure 7C. Expression of KLRK1 and GZMB on splenic CD8+ T cells. Left: representative staining. Right: percentage of KLRK1+ GZMB+ cells out of total CD8+ T cells. Kruskal–Wallis test, p-value is shown in italics, median is shown. (C) On day 0, C57Bl/6J mice were inoculated with B16F10 melanoma cells. On day 6, mice received doxorubicin (Dox) with/without anti-CD4 or anti-CD8 depletion mAb. On three consecutive days, mice were treated with IL-2/JES6 (see scheme Figure 7D). Survival curves. n = 8 mice per group in one experiments. The data shown here partially overlap with data shown in Figure 7E. There were two experiments in total, but only the second experiment had the mouse groups with the depletion of CD8+ or CD4+ cells. Figure 7E shows pooled data for all conditions included in both experiments. Here, results from the second experiment are shown. Statistical significance was calculated by log-rank (Mantel–Cox) test (p-value is shown in italics). (D) Tumor volume recorded on day 13 or 14 in the experiments shown in Figure 7E. Kruskal–Wallis test (p-value is shown in italics) with Dunn’s multiple comparison post-test (*<0.05, ***<0.001), median is shown. Control n = 15, Dox n = 16, Dox + IL-2/JES6 n=15 in two independent experiments. (E) Tumor volume growth in the experiment shown in Figure 7F–H. On day 11, tumors were harvested for flow cytometry analysis. n = 8 per group in two independent experiments. (F) Addition data for the experiment shown in Figure 7F–H. Expression of KLRK1 and CD49d on splenic CD8+ T cells. Left: representative staining. Right: percentage of KLRK1+ CD49d- and KLRK1+ CD49d+ cells out of total CD8+ T cells. Kruskal–Wallis test (p-value is shown in italics), median is shown.
less